



## Abivax to attend the J.P. Morgan 41st Annual Healthcare Conference

December 14, 2022

**Abivax's senior executive management will attend the J.P. Morgan 41st Annual Healthcare Conference and the 12th Annual LifeSci Partners Corporate Access Event from January 9-12 in San Francisco, US**

**PARIS, France, December 14, 2022 – 06:00 p.m. (CEST)** – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, today announces that its senior executive management will attend the J.P. Morgan 41st Annual Healthcare Conference and the 12th Annual LifeSci Partners Corporate Access Event, both taking place from January 9-12, 2023, in San Francisco, California, US.

The Abivax management team will be available for 1:1 meetings during the conferences in San Francisco. Interested investors and third parties can request meetings through the [LifeSci CAE 2023 Registration platform](#).

**Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax said:** *"We are very much looking forward to exchanging with our existing and potential new investors in San Francisco. We will seize the opportunity to discuss Abivax's financing options in order to refine our approach and our financial strategy in the near future. Top priority of this financing strategy is the funding of our ongoing global phase 3 program with obefazimod for the treatment of ulcerative colitis. At present, the recruitment of patients in the US is processing according to plan, and we expect the study centers in Europe to start enrollment of patients beginning of 2023."*

The LifeSci Partners Corporate Access Event will be held in person at the Beacon Grand Hotel (formerly the Sir Francis Drake), 450 Powell Street in San Francisco during the week of the J.P. Morgan Healthcare Conference. The LifeSci event will feature more than 200 innovative publicly traded and privately held biotechnology, medical technology, pharmaceutical, life sciences, and digital health companies from across the globe. It will include in-person 1:1 meetings with senior management teams showcasing the most relevant topics impacting the life sciences industry today.

\*\*\*\*\*

### About Abivax ([www.abivax.com](http://www.abivax.com))

Abivax is a phase 3 clinical stage biotechnology company, focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases. Abivax, founded by Truffle Capital, is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, obefazimod (ABX464) to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at [www.abivax.com](http://www.abivax.com). Follow us on Twitter @ABIVAX\_.

### Contacts

**Abivax Communications**  
Regina Jehle  
[regina.jehle@abivax.com](mailto:regina.jehle@abivax.com)  
+33 6 24 50 69 63

**Investors LifeSci Advisors**  
Ligia Vela-Reid  
[lvela-reid@lifesciadvisors.com](mailto:lvela-reid@lifesciadvisors.com)  
+44 7413 825310

**Press Relations & Investors Europe MC Services AG**  
Anne Hennecke  
[anne.hennecke@mc-services.eu](mailto:anne.hennecke@mc-services.eu)  
+49 211 529 252 22

**Public Relations France Actifin**  
Ghislaine Gasparetto  
[ggasparetto@actifin.fr](mailto:ggasparetto@actifin.fr)  
+33 6 21 10 49 24

**Public Relations France Primatice**  
Thomas Roborel de Climens  
[thomasdeclimens@primatice.com](mailto:thomasdeclimens@primatice.com)  
+33 6 78 12 97 95

**Public Relations USA Rooney Partners LLC**  
Jeanene Timberlake  
[jtimberlake@rooneypartners.com](mailto:jtimberlake@rooneypartners.com)  
+1 646 770 8858

### DISCLAIMER

*This press release contains forward-looking statements, forecasts and estimates (including patient recruitment) with respect to certain of the Company's programs. Although Abivax' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its registration document (Document d'Enregistrement Universel). These risks, contingencies and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development including further assessment by the company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction, in particular in France. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own*

*judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.*